Ublituximab and Umbralisib in Relapsed/Refractory B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia By admin / 11/21/2019
Combination of Umbralisib, Ublituximab, and Bendamustine is Safe and Highly Active in Patients with Advanced DLBCL and Follicular Lymphoma By admin / 12/03/2018
Combination of TGR-1202, Ublituximab, and bendamustine is safe and highly active in patients with advanced DLBCL and follicular lymphoma By admin / 06/24/2017
Combination of TGR-1202, Ublituximab, and Bendamustine is safe and highly active in patients with advanced DLBCL and Follicular Lymphoma By admin / 06/15/2017
Combination of Ublituximab, TGR-1202 and Bendamustine Demonstrates Significant Activity in Patients with Advanced DLBCL and Follicular Lymphoma. By admin / 12/05/2016
Ublituximab + TGR-1202 Demonstrates Activity and Favorable Safety Profile in Relapsed/Refractory B-Cell NHL and High-Risk CLL. By admin / 06/20/2015
Ublituximab + TGR-1202 Demonstrates Activity and Favorable Safety Profile in Relapsed/Refractory B-Cell NHL and High-Risk CLL. By admin / 06/14/2015
Ubliuximab +TGR-1202 Demonstrates Activity and Favorable Safety Profile in Relapsed/Refractory B-Cell NHL and High-Risk CLL. By admin / 06/02/2015
Ublituximab + TGR-1202 Demonstrates Activity and a Favorable Safety Profile in Relapsed/Refractory B-Cell NHL and High-Risk CLL: Phase I Results. By admin / 03/08/2015
Ublituximab, a Novel Glycoengineered Anti-CD20 Monoclonal Antibody (mAb), in Combination with TGR-1202, a Next Generation Once Daily PI3K Delta Inhibitor, Demonstrate Activity in Heavily Pre-Treated and High-Risk Chronic Lymphocytic Leukemia (CLL) and B-Cell Lymphoma. By admin / 12/09/2014
